AbbVie vs Novartis

AbbVie (ABBV), health care, and Novartis (NVS), health care, side by side on market value, valuation, margins, balance sheet and price change. Higher and lower are marked; neither is called better.

AbbVie is worth $518.6B on the stock market and Novartis $301.5B: AbbVie is valued at 72% more. AbbVie trades at 50.5 times earnings and Novartis at 30.5; operating margins in their latest fiscal years were 24.6% and 32.4%. Over the past year AbbVie's share price has moved +25.9% and Novartis's +25.1%.

Key facts

AbbVie market value
$518.6B
Novartis market value
$301.5B
AbbVie P/E
50.5
Novartis P/E
30.5
AbbVie revenue
$61.2BFY to 2025-12-31
Novartis revenue
$54.5BFY to 2025-12-31
Superinvestors holding both
4

Market values as of .

AbbVie vs Novartis: every measure side by side
Measure AbbVie Novartis
SectorHealth CareHealth Care
Country United States Switzerland
Fiscal year ends2025-12-312025-12-31
Size
Market cap$518.6Bhigher$301.5Blower
Revenue$61.2Bhigher$54.5Blower
Earnings$4.2Blower$14Bhigher
Employees57,000lower75,267higher
Total assets$134Bhigher$110.9Blower
Valuation
P/E50.5higher30.5lower
P/S8.5higher5.5lower
P/B——
Dividend yield2.35%—
Profitability
Operating margin24.6%lower32.4%higher
Balance sheet
Net assets-$3.3Blower$46.1Bhigher
Total liabilities$137.2Bhigher$64.4Blower
Total debt$67.5Bhigher$28.7Blower
Cash on hand$5.2Blower$11.4Bhigher
Price change
Today-0.39%lower-0.35%higher
1 year+25.9%higher+25.1%lower

Market value, P/E, P/B, dividend yield and price changes are from live quotes (Yahoo Finance; prices may be delayed 15 minutes or more). Revenue, earnings, operating margin and the balance-sheet figures are from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day. P/S sets today's market value against the latest fiscal year's revenue. “Higher” and “lower” compare the two numbers only; a higher P/E or more debt is not better. Dividend yield and P/B are shown only for companies based in the US. A dash means no figure is on file.

Loading the one-year price chart…

Which superinvestors hold them

From each tracked investor's latest 13F filing. A 13F lists long positions in US-listed shares at a quarter end, filed up to 45 days later.

Percentages are each holding's share of that investor's reported portfolio (under "Both": AbbVie / Novartis). Who owns ABBV · Who owns NVS

Further comparisons

Learn

Questions and answers

Which is bigger, AbbVie or Novartis?

By market value, AbbVie is the larger: $518.6B against $301.5B for Novartis. By revenue in its latest fiscal year, AbbVie is the larger: $61.2B against $54.5B for Novartis.

Which has the higher P/E ratio?

AbbVie: 50.5, against 30.5 for Novartis. A higher P/E means the market pays more for each dollar of the last twelve months' earnings; on its own it does not say which is the better value.

Which has the higher operating margin?

Novartis: 32.4%, against 24.6% for AbbVie. Operating margin is operating income as a share of revenue in the latest fiscal year.

Which has more debt?

AbbVie: $67.5B, against $28.7B for Novartis. Total debt is borrowings at the end of the latest fiscal year, as each company reported it; it is not set against cash here.

Which superinvestors own both AbbVie and Novartis?

In their latest 13F filings, Ken Fisher, Larry Robbins, Murray Stahl and Rajiv Jain hold both.

Cite this page

Funkfolio, “AbbVie vs Novartis”, data as of 17 November 2026. https://funkfolio.com/compare/abbv-vs-nvs

Underlying data: Yahoo Finance quotes; SEC annual reports collected 2026-11-12; 13F filings.